Acticor Biotech, a biotechnology company focused on the treatment of acute ischemic stroke, today announced that it has raised €1,5M from CapDecisif Management. Acticor Biotech had already secured €1,4M in the first closing, which brings the total amount invested to €2,9M.
This new fund will enable Acticor Biotech to pursue the development of its lead candidate ACT017 in Acute Ischemic Stroke, toward its entry in Phase I Clinical Trial.
Thanks to encouraging pre-clinical results and positive regulatory meetings, Acticor Biotech should start its Phase I 6 months earlier than originally planned. The first subject could thus be scheduled for early Q4 2017.
